Genscript Biotech 

$1.42
5
+$0.12+9.23% Wednesday 19:33

Statistics

Day High
1.4
Day Low
1.4
52W High
2.42
52W Low
1.28
Volume
120
Avg. Volume
1,360
Mkt Cap
3.09B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 17
$0
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

15MarExpected
Q4 2022
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-1.8
2.63
7.07
11.5
Expected EPS
-0.2348031
Actual EPS
-1.8001571

Financials

286.12%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
2.07BRevenue
5.92BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GNNSF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap19.48B
Illumina provides genomic sequencing solutions and competes in the biotechnology tools space, similar to Genscript's offerings in genomics and proteomics.
Thermo Fisher Scientific
TMO
Mkt Cap182.57B
Thermo Fisher Scientific offers a range of biotechnology products, including gene synthesis and editing tools, directly competing with Genscript's biotech services.
Qiagen NV
QGEN
Mkt Cap8.46B
Qiagen is a major player in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, overlapping with Genscript's molecular biology products.
Bio-Rad Laboratories
BIO
Mkt Cap7.56B
Bio-Rad Laboratories manufactures and supplies products and systems used for gene expression, competing in the same biotech instrumentation sector as Genscript.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences offers genomic analysis systems, which compete with Genscript's services in the genomics field.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a leading developer of CRISPR gene editing technology, a direct competitor to Genscript's CRISPR-based product offerings.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine is involved in gene editing technology, particularly CRISPR, which is a growing area of competition for Genscript's gene and cell therapy services.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics focuses on genomic medicine, including gene editing, competing with Genscript's genomic and genetic engineering technologies.
Twist Bioscience
TWST
Mkt Cap3.08B
Twist Bioscience operates in the synthetic biology field, providing synthetic DNA tools that are competitive with Genscript's gene synthesis services.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is focused on the development of gene-based medicines using CRISPR/Cas9 technology, competing with Genscript's similar technological applications in gene therapy.

About

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through three segments: Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products. The Life Science Services and Products segment provides products and services in various categories, including gene synthesis, oligonucleotide synthesis, peptide synthesis, protein engineering, antibody development, and life-science equipment and consumables, such as molecular diagnostics tools and genome editing materials for biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and the food industry. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Show more...
CEO
Mr. Jiange Meng
Employees
5568
Country
KY
ISIN
KYG3825B1059

Listings

0 Comments

Share your thoughts

FAQ

What is Genscript Biotech stock price today?
The current price of GNNSF is $1.42 USD — it has increased by +9.23% in the past 24 hours. Watch Genscript Biotech stock price performance more closely on the chart.
What is Genscript Biotech stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genscript Biotech stocks are traded under the ticker GNNSF.
Is Genscript Biotech stock price growing?
GNNSF stock has risen by +0% compared to the previous week, the month change is a -18.86% fall, over the last year Genscript Biotech has showed a -25.26% decrease.
What is Genscript Biotech market cap?
Today Genscript Biotech has the market capitalization of 3.09B
When is the next Genscript Biotech earnings date?
Genscript Biotech is going to release the next earnings report on August 17, 2026.
What were Genscript Biotech earnings last quarter?
GNNSF earnings for the last quarter are -0.23 USD per share, whereas the estimation was -0.03 USD resulting in a -666.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Genscript Biotech revenue for the last year?
Genscript Biotech revenue for the last year amounts to 2.07B USD.
What is Genscript Biotech net income for the last year?
GNNSF net income for the last year is 5.92B USD.
Does Genscript Biotech pay dividends?
Yes, GNNSF dividends are paid annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Genscript Biotech have?
As of April 06, 2026, the company has 5,568 employees.
In which sector is Genscript Biotech located?
Genscript Biotech operates in the Health Care sector.
When did Genscript Biotech complete a stock split?
Genscript Biotech has not had any recent stock splits.
Where is Genscript Biotech headquartered?
Genscript Biotech is headquartered in Nanjing, KY.